Cicero completed multiple online surveys and in-depth interviews on behalf of this pharmaceutical company, surrounding prostate cancer research. For example, in one study, Cicero surveyed 100 oncology doctors that specialized in prostate cancer to understand their tendency to biopsy under differing circumstances. They were also asked for their opinion of different laboratories and their standard procedures for evaluating biopsy specimens. The information from these studies has enabled the company to continue their research on specific biomarkers that are believed to accurately predict cancer within the prostate even when it is not present in a specific biopsy sample.
Insights & Publications
Cicero Institute is our center for sharing knowledge, research, and thought leadership. Cicero Institute publishes data-driven industry insights to help drive success and improve efficiency in a fast-paced and challenging marketplace.